U.S. FDA Approves Mydayis™ (mixed salts of single entity amphetamine product)
Shire plc (LSE: SHP, NASDAQ: SHPG) announced on June 20, 2017 that the U.S. Food and Drug Administration (FDA) has approved Mydayis™ for treatment of ADHD.
Q: Indications for Mydayis™ use?
- Patients 13 years and older with ADHD
- Not indicatied for use in children 12 years and younger.
Q: What is this US FDA approval based on?
- This is based on results from 16 clinical studies evaluating Mydayis in more than 1,600 subjects, including adolescents (aged 13 to 17 years) and adults with ADHD.
- In pivotal, placebo-controlled clinical studies, Mydayis significantly improved symptoms of ADHD, as measured by the ADHD-RS-IV and the Permanent Product Measure of Performance (PERMP), in adults and adolescents.
- Improvement on the PERMP, an objective, validated, skill-adjusted math test that measures attention in ADHD patients, reached statistical significance beginning at 2 or 4 hours post-dose and lasting up to 16 hours post-dose.
Q: What are the most common adverse reactions (incidence ≥5% and at a rate at least twice placebo)?
- Decreased appetite, decreased weight
- Dry mouth
- Increased heart rate
Q: What are the contraindications for Mydayis™ use?
- Allergic to amphetamine or any of the ingredients in Mydayis.
- Taking, or have taken within the past 14 days monoamine oxidase inhibitor (MAOI).
Q: When will Mydayis™ be available in United States?
- Shire expects to make Mydayis commercially available in the United States in the third quarter of 2017.
Note: Mydayis, other amphetamine containing medicines, and methylphenidate have a high chance for abuse and can cause physical and psychological dependence.
Source: Shire Press Release. Lexington, Mass., USA – June 20, 2017
Please do post your questions or comments below.
Dr. Harvinder Singh, M.D. (Admin)
Enroll in our online course to have access to all important clinically relevant psychiatry topics in one place.